Cue Biopharma (CUE) Total Liabilities (2017 - 2025)
Cue Biopharma (CUE) posted Total Liabilities of $15.8 million for Q4 2025, down 14.23% sequentially from $18.4 million in Q3 2025, and up 7.41% YoY from $14.7 million in Q4 2024.
Cue Biopharma (CUE) Total Liabilities (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Total Liabilities for 9 years, with the latest figure at $15.8 million in Q4 2025.
- Quarterly Total Liabilities rose 7.41% year-over-year to $15.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.8 million (up 7.41% YoY) and the FY2025 annual result came in at $15.8 million, up 7.41% from the prior year.
- Total Liabilities fell to $15.8 million in Q4 2025 per CUE's latest filing, from $18.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $27.2 million in Q2 2023 and troughed at $14.7 million in Q4 2024.
- A 5-year average of $21.3 million and a median of $21.6 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities soared 66.3% in 2022, then tumbled 39.9% in 2024.
- Over 5 years, Total Liabilities stood at $17.9 million in 2021, then jumped by 42.95% to $25.6 million in 2022, then declined by 4.52% to $24.4 million in 2023, then sank by 39.9% to $14.7 million in 2024, then gained by 7.41% to $15.8 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $15.8 million, $18.4 million, and $22.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | 28.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.78 Mn |
| Sep 30, 2025 | 18.40 Mn |
| Jun 30, 2025 | 22.55 Mn |
| Mar 31, 2025 | 15.67 Mn |
| Dec 31, 2024 | 14.69 Mn |
| Sep 30, 2024 | 19.44 Mn |
| Jun 30, 2024 | 20.71 Mn |
| Mar 31, 2024 | 23.91 Mn |
| Dec 31, 2023 | 24.45 Mn |
| Sep 30, 2023 | 26.22 Mn |
| Jun 30, 2023 | 27.16 Mn |
| Mar 31, 2023 | 26.67 Mn |
| Dec 31, 2022 | 25.60 Mn |
| Sep 30, 2022 | 25.54 Mn |
| Jun 30, 2022 | 24.99 Mn |
| Mar 31, 2022 | 26.03 Mn |
| Dec 31, 2021 | 17.91 Mn |
| Sep 30, 2021 | 15.36 Mn |
| Jun 30, 2021 | 16.76 Mn |
| Mar 31, 2021 | 19.05 Mn |